FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 18, 2020--
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the following conferences in February and March.
SVB Leerink 9th Annual Global Healthcare Conference
Location: New York, NY
Presentation date: Wednesday February 26, 2020
Presentation time: 9:30 a.m. ET
Cowen 40th Annual Healthcare Conference
Location: Boston, MA
Presentation date: Monday March 2, 2020
Presentation time: 2:10 p.m. ET
Raymond James 41st Annual Institutional Investors Conference
Location: Orlando, FL
Presentation date: Wednesday March 4, 2020
Presentation time: 9:15 a.m. ET
A live audio webcast and archive of the presentations outline above will be available at http://ir.mirumpharma.com
Additionally, the company will be participating the 32nd Annual ROTH Conference, and will be on a panel on Monday March 16 at 11:00 a.m. discussing Orphan Therapeutics.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005870/en/
Source: Mirum Pharmaceuticals, Inc.
Heidi Chokeir, Ph.D.
Ian Clements, Ph.D.